Latest Strategic Reviews News

Pathkey.AI appoints Andrew Farnsworth as CEO, leveraging his defence and AI expertise to drive commercialisation of TrialKey and Chipforge platforms.

Besra Gold appoints Dr Raymond Shaw as CEO, leveraging his four decades of experience to steer the Bau Gold project through ongoing operational and strategic hurdles.

Zenith Minerals has completed the acquisition of a critical mining lease at its Consolidated Dulcie Gold Project, enabling control of the entire ~6km mineralised corridor and setting up a targeted drilling campaign to test a high-potential untested strike segment.

Altech Batteries has decided to discontinue its Silumina AnodesTM project after six years, shifting full focus to its CERENERGY® solid-state battery technology amid ongoing joint venture talks.

Pengana International Equities (ASX:PIA) unveils a comprehensive capital management plan offering shareholders an equal-access off-market buy-back at after-tax NTA, a fully franked special dividend, and appoints Antipodes Global Investment Management to steer its portfolio.

Proteomics International Laboratories (ASX:PIQ) has denied any undisclosed material information following a sharp share price drop and heightened trading activity, pointing instead to recent strategic updates and organisational changes.

Zenith Minerals has initiated a strategic review to explore corporate and asset options aimed at maximising shareholder value, centred on its Consolidated Dulcie Gold Project which hosts a 675,000-ounce gold resource.

Arovella Therapeutics has named Dr Nicole Van Der Weerden as acting CEO following Dr Michael Baker’s departure, positioning her to steer the company through the critical phase I trial of its CAR-iNKT therapy ALA-101.

Amcor posted a 77% jump in Q3 net sales fueled by the Berry acquisition, delivering synergy gains above expectations and updating fiscal 2026 guidance amid geopolitical headwinds.

Beamtree Holdings has landed a $2 million contract with Saudi Arabia’s Fakeeh Care Group, while revising down its FY26 ARR growth guidance and outlining cost-cutting measures as part of an ongoing strategic review.

Arovella Therapeutics undergoes a major board overhaul and CEO resignation following a shareholder push, as the company embarks on a strategic review of its cell therapy platform.

The Hydration Pharmaceuticals Company Limited (ASX: HPC) has had its trading suspension lifted as of 4 May 2026, following the lodgement of its delayed Annual Report revealing a $2.86 million net loss.